CAR-T Cell Therapies Entering the Mainstream of Cancer Clinical Trials & Treatment
Video
CAR-T Cell Therapies Entering the Mainstream of Cancer Clinical Trials & Treatment
Video Interview with Tanmay Jain, Sr. Director of Trial Design Solutions within Medidata AI
Despite their immense promise and transformative potential in the field of oncology, CAR-T cell therapies have presented numerous challenges for clinical trials and developers since the first CAR-T patient was treated a decade ago. Adverse events such as Cytokine Release Syndrome (CRS) have limited who can be treated with CAR-T cell therapies, where these treatments can occur, and who is financially eligible. However, Medidata AI’s predictive trial design empowers developers to learn from past successes and failures of CAR-T clinical trials, ultimately facilitating efficient and safer future trials by identifying the patients at highest risk of developing adverse events such as CRS and better managing these patients with preemptive treatment.
